OBJECTIVE: To identify a pre-HAART gene expression signature in peripheral blood mononuclear cells (PBMCs) predictive of CD4 T-cell recovery during HAART in HIV-infected individuals. DESIGN: This retrospective study evaluated PBMC gene expression in 24 recently HIV-infected individuals before the initiation of HAART to identify genes whose expression is predictive of CD4 T-cell recovery after 48 weeks of HAART. METHODS: The change in CD4 T-cell count (DeltaCD4) over the 48-week study period was calculated for each of the 24 participants. Twelve participants were assigned to the 'good' (DeltaCD4 > or = 200 cells/microl) and 12 to the 'poor' (DeltaCD4 < 200 cells/microl) CD4 T-cell recovery group. Gene expression profiling of the entire transcriptome using Illumina BeadChips was performed with PBMC samples obtained before HAART. Gene expression classifiers capable of predicting CD4 T-cell recovery group (good vs. poor), as well as the specific DeltaCD4 value, at week 48 were constructed using methods of Class Prediction. RESULTS: The expression of 40 genes in PBMC samples taken before HAART predicted CD4 T-cell recovery group (good vs. poor) at week 48 with 100% accuracy. The expression of 22 genes predicted a specific DeltaCD4 value for each HIV-infected individual that correlated well with actual values (R = 0.82). Predicted DeltaCD4 values were also used to assign individuals to good vs. poor CD4 T-cell recovery groups with 79% accuracy. CONCLUSION: Gene expression in PBMCs can be used as biomarkers to successfully predict disease outcomes among HIV-infected individuals treated with HAART.
OBJECTIVE: To identify a pre-HAART gene expression signature in peripheral blood mononuclear cells (PBMCs) predictive of CD4 T-cell recovery during HAART in HIV-infected individuals. DESIGN: This retrospective study evaluated PBMC gene expression in 24 recently HIV-infected individuals before the initiation of HAART to identify genes whose expression is predictive of CD4 T-cell recovery after 48 weeks of HAART. METHODS: The change in CD4 T-cell count (DeltaCD4) over the 48-week study period was calculated for each of the 24 participants. Twelve participants were assigned to the 'good' (DeltaCD4 > or = 200 cells/microl) and 12 to the 'poor' (DeltaCD4 < 200 cells/microl) CD4 T-cell recovery group. Gene expression profiling of the entire transcriptome using Illumina BeadChips was performed with PBMC samples obtained before HAART. Gene expression classifiers capable of predicting CD4 T-cell recovery group (good vs. poor), as well as the specific DeltaCD4 value, at week 48 were constructed using methods of Class Prediction. RESULTS: The expression of 40 genes in PBMC samples taken before HAART predicted CD4 T-cell recovery group (good vs. poor) at week 48 with 100% accuracy. The expression of 22 genes predicted a specific DeltaCD4 value for each HIV-infected individual that correlated well with actual values (R = 0.82). Predicted DeltaCD4 values were also used to assign individuals to good vs. poor CD4 T-cell recovery groups with 79% accuracy. CONCLUSION: Gene expression in PBMCs can be used as biomarkers to successfully predict disease outcomes among HIV-infected individuals treated with HAART.
Authors: Hendrik Streeck; Heiko Jessen; Galit Alter; Nickolas Teigen; Mike T Waring; Arne Jessen; Ingrid Stahmer; Jan van Lunzen; Mathias Lichterfeld; Xiaojiang Gao; Todd M Allen; Mary Carrington; Bruce D Walker; Juergen K Rockstroh; Marcus Altfeld Journal: J Infect Dis Date: 2006-08-15 Impact factor: 5.226
Authors: Stephen J Glatt; Ian P Everall; William S Kremen; Jacques Corbeil; Roman Sásik; Negar Khanlou; Mark Han; Choong-Chin Liew; Ming T Tsuang Journal: Proc Natl Acad Sci U S A Date: 2005-10-13 Impact factor: 11.205
Authors: Miguel Goicoechea; Davey M Smith; Lin Liu; Susanne May; Allan R Tenorio; Caroline C Ignacio; Alan Landay; Richard Haubrich Journal: J Infect Dis Date: 2006-05-18 Impact factor: 5.226
Authors: Natalie C Twine; Jennifer A Stover; Bonnie Marshall; Gary Dukart; Manuel Hidalgo; Walter Stadler; Theodore Logan; Janice Dutcher; Gary Hudes; Andrew J Dorner; Donna K Slonim; William L Trepicchio; Michael E Burczynski Journal: Cancer Res Date: 2003-09-15 Impact factor: 12.701
Authors: W M El-Sadr; J D Lundgren; J D Neaton; F Gordin; D Abrams; R C Arduino; A Babiker; W Burman; N Clumeck; C J Cohen; D Cohn; D Cooper; J Darbyshire; S Emery; G Fätkenheuer; B Gazzard; B Grund; J Hoy; K Klingman; M Losso; N Markowitz; J Neuhaus; A Phillips; C Rappoport Journal: N Engl J Med Date: 2006-11-30 Impact factor: 91.245
Authors: Seong-Heon Wie; Pinyi Du; Tiffany Q Luong; Steffney E Rought; Nadejda Beliakova-Bethell; Jean Lozach; Jacques Corbeil; Richard S Kornbluth; Douglas D Richman; Christopher H Woelk Journal: J Interferon Cytokine Res Date: 2012-12-31 Impact factor: 2.607
Authors: Nadejda Beliakova-Bethell; Jin X Zhang; Akul Singhania; Vivian Lee; Valeri H Terry; Douglas D Richman; Celsa A Spina; Christopher H Woelk Journal: AIDS Date: 2013-01-02 Impact factor: 4.177
Authors: Julio A Gutierrez; Krysten A Jones; Roxana Flores; Akul Singhania; Christopher H Woelk; Robert T Schooley; David L Wyles Journal: J Virol Antivir Res Date: 2014-10-06
Authors: Marta Massanella; Akul Singhania; Nadejda Beliakova-Bethell; Rose Pier; Steven M Lada; Cory H White; Josué Pérez-Santiago; Julià Blanco; Douglas D Richman; Susan J Little; Christopher H Woelk Journal: Antiviral Res Date: 2013-08-06 Impact factor: 5.970
Authors: Suganya Viriyakosol; Akul Singhania; Joshua Fierer; Jonathan Goldberg; Theo N Kirkland; Christopher H Woelk Journal: BMC Microbiol Date: 2013-05-28 Impact factor: 3.605